EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Classification of Endometrial Carcinomas: Review and Recent Updates

Anita Kumari, Himani Kumar iD, Samuel E Harvey iD, Deyin Xing, Zaibo Li iD

Cancers · 24.12.2025 · 18 (1) · 51

DOI: 10.3390/cancers18010051 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.12.2025. Verfasst von Anita Kumari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Ohio State University, Columbus, OH 43210, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial carcinoma (EC) continues to represent a major cause of gynecologic cancer–related mortality among women worldwide. Its multifactorial etiopathogenesis and underlying molecular heterogeneity have been the focus of extensive investigation. While traditional histological classification provides essential diagnostic insight, it is limited in predicting prognosis and therapeutic response due to significant interobserver variability. Recent advances in molecular biology and cancer genomics have profoundly enhanced understanding of EC pathogenesis. The Cancer Genome Atlas (TCGA) project delineated four distinct molecular subtypes of EC, POLE ultra-mutated, microsatellite instability hypermutated (MSI-H), copy number low (CNL) and copy number high (CNH), each defined by unique genomic alterations, histopathologic features, and clinical behaviors. These molecular groups demonstrate significant prognostic and therapeutic implications, correlating with differential outcomes and treatment responses. This review summarizes current evidence on the genomic landscape of endometrial carcinoma and underscores the pivotal role of molecular classification in improving diagnostic accuracy, prognostic stratification, and personalized therapy. Ongoing research into molecular biomarkers holds promise for refining patient management and optimizing clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

POLE-ultramutatedendometrial carcinomamicrosatellite instabilityp53

Autor:innen und Institutionen

  • Department of Pathology, The Ohio State University, Columbus, OH 43210, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

ORCID-Profile: Himani Kumar, Samuel E Harvey, Zaibo Li

Zitieren

APA

Kumari, A., Kumar, H., Harvey, S. E., Xing, D., & Li, Z. (2025). Molecular Classification of Endometrial Carcinomas: Review and Recent Updates. Cancers, 18(1), 51. https://doi.org/10.3390/cancers18010051

Vancouver

Kumari A, Kumar H, Harvey SE, Xing D, Li Z. Molecular Classification of Endometrial Carcinomas: Review and Recent Updates. Cancers. 2025;18(1):51. doi:10.3390/cancers18010051

BibTeX
@article{Kumari2025,
  author = {Kumari, Anita and Kumar, Himani and Harvey, Samuel E and Xing, Deyin and Li, Zaibo},
  title = {Molecular Classification of Endometrial Carcinomas: Review and Recent Updates},
  journal = {Cancers},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {51},
  doi = {10.3390/cancers18010051}
}
Kostenlos starten →